460 related articles for article (PubMed ID: 16413056)
1. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
2. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
3. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
5. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
[TBL] [Abstract][Full Text] [Related]
6. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
[TBL] [Abstract][Full Text] [Related]
8. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
9. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.
Sousa AB; Fernandes JP; Costa I; Ferreira G; Nunes O; Ribeiro P; Neves A; Cruz E; Aveiro F; Rodrigues AS; Bernardo M; Conduto A; Gonçalves AJ; Monteiro A; Sousa M; Soares VH; Veiga J; Gouveia J
Hematol Cell Ther; 1998 Apr; 40(2):63-6. PubMed ID: 9615248
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
12. Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
Baek JH; Sohn SK; Kim DH; Kim JG; Yang DH; Kim YK; Lee JJ; Kim HJ
Acta Haematol; 2007; 117(2):109-14. PubMed ID: 17135724
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS
Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533
[TBL] [Abstract][Full Text] [Related]
14. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
[TBL] [Abstract][Full Text] [Related]
17. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
Hiddemann W; Wörmann B; Reuter C; Schleyer E; Zühlsdorf M; Böckmann A; Büchner T
Semin Oncol; 1994 Dec; 21(6 Suppl 16):33-8. PubMed ID: 7528449
[TBL] [Abstract][Full Text] [Related]
18. rHuGM-CSF after high-dose chemotherapy in post-remission acute leukemia.
Hurtado R; Candelaria M; Vargas F; Majluf A; Bolaños F; Labardini JR
Stem Cells; 1995 Mar; 13(2):112-22. PubMed ID: 7787778
[TBL] [Abstract][Full Text] [Related]
19. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
20. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E
N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
